Ozempic^® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:

• Diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance
• Metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control
• Metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control
• Basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control

Please consult the Product Monograph at OzempicPM-E.ca or here for more information on:

• Contraindications in personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and pregnancy or breastfeeding
• A serious warning on risk of thyroid C-cell tumours
• Other relevant warnings and precautions relating to intramuscular administered, pancreatitis, hypoglycemia with concomitant use of insulin secretagogues or insulin, use with other incretin drugs, hypersensitivity, diabetic retinopathy (in patients with history of disease monitor for progression), renal impairment (severe GI adverse reactions warrant monitoring of renal function; use in end-stage disease), CV effects (increased heart rate; PR interval prolongation), and hepatic insufficiency
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

Quebec (RAMQ*) Exceptional Medication: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated or ineffective. Authorization is given for a weekly maximum dose of 1 mg. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.

Continue

* Official mark of the Régie de l’assurance maladie du Québec.